erythropoietins


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to erythropoietins: Hemopoietin, erythropoietin stimulating factor

erythropoietins

Hormones, produced mainly in the kidneys, that stimulates red blood cell production (erythropoiesis) in the bone marrow. The amount of hormone produced is based on monitoring of the blood flowing through the kidneys for oxygen concentration.
References in periodicals archive ?
Contract notice: Framework agreement erythropoietin.
This article charts the history of anemia management in patients with ESRD, discusses the receptor science behind the discovery of erythropoietin and subsequent development of ESA therapy, and briefly reviews the mechanism of action and select attributes of ESAs.
In 1957, a series of experiments by Jacobson and colleagues established that during hypoxia, there is an absence of erythropoietin activity in nephrectomized animals, thus establishing the role of the kidney in erythropoiesis (Jacobson, Goldwasser, Fried, & Plzak, 1957).
The report launched a flurry of investigations by the companies that make and market recombinant human erythropoietin.
Based on this, experts are now urging physicians to administer erythropoietin intravenously when feasible.
Recombinant human erythropoietin (rHuEPO) is a sialoglycoprotein hormone that appears to be immunologically and biologically equivalent to the endogenous compound, enhancing erythropoiesis dose-proportionally.
Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins
Table 2: World Market for Erythropoietins (2000-2010): Geographic Regions Ranked by CAGR - Europe, US, Japan and Rest of World (includes corresponding Graph/Chart) II-14 Colony Stimulating Factors II-14 Granulocyte-Colony Stimulating Factor II-14 Granulocyte Macrophage-Colony Stimulating Factor II-14 Other Colony Stimulating Factors II-14 Macrophage Colony Stimulating Factor (M-CSF) II-15 Key Functions of M-CSF II-15 Side-Effects of Colony-Stimulating Factors II-15
A sharp increase in the incidence of PRCA has been observed in patients with chronic kidney disease (CKD) who are treated with recombinant human erythropoietin (rHuEPO) for chronic renal anemia (Bergrem, Danielson, Eckardt, Kurtz, & Stridsberg, 1993; Casadevall, 2002; Casadevall et al.
The erythropoiesis stimulating effects of erythropoietin
The first step in treatment is stopping erythropoietin as soon as PRCA is diagnosed.
Amgen revolutionized anemia treatment with the development of a recombinant human erythropoietin, epoetin alfa, which is currently marketed in the U.